Business Context and Reporting Period
Company: I-Mab (Novabridge Biosciences is not the registrant; the filing is for I-Mab, a Cayman Islands exempted company).
Filing Type: Form 20-F Annual Report.
Period: Fiscal year ended December 31, 2024.
Key Event: In April 2024, the company completed the divestiture of its Greater China assets and business operations to TJ Biopharma (Hangzhou) Co., Ltd. ("TJBio Hangzhou"). Consequently, the company has transitioned to a U.S.-based biotech focused on its global portfolio, with operations primarily conducted through its U.S. subsidiary. The financial results for the divested operations are reported as discontinued operations.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 (Continuing Ops) | 2023 (Continuing Ops) | 2022 (Continuing Ops) |
|---|---|---|---|
| Revenue | $0 | $0.6 million | $(1.6 million) |
| Net Loss (Continuing Ops) | $(49.7 million) | $(82.2 million) | $(141.2 million) |
| Net Loss (Total, incl. Discontinued) | $(22.2 million) | $(207.7 million) | $(371.1 million) |
| Net Cash Used in Operating Activities (Continuing) | $(52.7 million) | $(72.7 million) | $(49.6 million) |
| Cash, Cash Equivalents & Short-Term Investments | $173.4 million | $310.7 million | $475.4 million |
| Total Assets | $212.7 million | $368.9 million | N/A |
| Total Liabilities | $11.5 million | $126.3 million | N/A |
Note: 2024 Net Loss includes a $27.5 million gain from discontinued operations (sale of Greater China assets), significantly reducing the total reported loss compared to continuing operations.
Material Changes vs. Prior Period
- Divestiture Impact: The April 2024 divestiture of Greater China assets resulted in a $34.4 million gain on sale (recorded in discontinued operations) and the cessation of consolidation for those entities. This fundamentally altered the company's cost structure and asset base.
- Revenue: Revenue from continuing operations dropped to zero in 2024 from $0.6 million in 2023, as the AbbVie collaboration revenue was recognized in prior periods and no new product revenue has been generated.
- Expenses: Research and Development (R&D) expenses remained relatively flat at $21.8 million in 2024 compared to $21.4 million in 2023. Administrative expenses increased to $29.7 million in 2024 from $28.2 million in 2023, primarily due to a $13.8 million increase in legal fees related to trade secret disputes, partially offset by lower employee-related expenses due to the divestiture and stock price decline.
- Goodwill Impairment: The $23.0 million goodwill impairment recorded in 2023 (due to the AbbVie termination) did not recur in 2024.
- Investments: The company recognized an $8.2 million unrealized loss on available-for-sale debt securities (investment in TJBio Hangzhou) in 2024, recorded in Other Comprehensive Loss.
Guidance, Outlook, and Risks
- Strategic Realignment: In January 2025, the company announced a "Realignment Plan" to focus resources on its lead program, givastomig (CLDN18.2 x 4-1BB bispecific antibody). This included a workforce reduction of approximately 27% and an expected annual operating expense savings of $3.0 million.
- Pipeline Focus: Development of uliledlimab has been paused pending data from TJ Biopharma's Phase 2 study in China. Ragistomig is being managed by partner ABL Bio.
- Liquidity: Management believes current cash and short-term investments of $173.4 million are sufficient to fund operations into 2027. However, the company expects to continue incurring losses and may require additional financing.
- Material Weaknesses: The company identified material weaknesses in internal controls over financial reporting related to ineffective information technology general controls (ITGCs) as of December 31, 2024. Remediation is underway.
- Nasdaq Compliance: The company received a notice from Nasdaq in March 2025 regarding non-compliance with the minimum bid price requirement (below $1.00 for 30 consecutive days). It has 180 days to regain compliance.
- Legal Proceedings: The company settled arbitration with non-participating shareholders of TJBio Hangzhou in late 2024. A trade secret misappropriation lawsuit against Inhibrx, Inc. resulted in a jury verdict in favor of the defendants in November 2024 regarding a portion of the claims.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $173.4 million cash balance against the burn rate of ~$52.7 million annually, considering the impact of the 27% workforce reduction.
- Nasdaq Status: Monitor the company's progress in regaining compliance with the $1.00 minimum bid price requirement by September 15, 2025, to avoid potential delisting.
- Internal Controls: Assess the timeline and effectiveness of remediation for the identified material weaknesses in IT general controls.
- Divestiture Contingencies: Review the terms of the $80 million contingent consideration from the Greater China divestiture and the likelihood of achieving regulatory/sales milestones.
- Legal Exposure: Monitor the status of the Inhibrx trade secret litigation and any potential appeals or further proceedings.
- Pipeline Progress: Track the Phase 1b dose escalation and expansion data for givastomig, expected in late 2025 and early 2026, as the primary driver for future value.